December 21st 2021
By Tony Hagen
The year 2021 brought several firsts in biosimilars and set the stage for expansion across therapeutic areas including diabetes and ophthalmology.
December 20th 2021
A trio of regulatory experts discuss the current standing of biosimilar policy in the United States and expectations going forward.
Investigators said pathologic complete response (pCR) improved in a trastuzumab biosimilar/pertuzumab trial when patients were preselected for a subtype of breast cancer.
December 16th 2021
Investigators said more evidence would help to convince clinicians of the safety of switching between biosimilar products.
December 15th 2021
Xbrane Biopharma of Stockholm, Sweden, said its next biosimilar candidates will target the demand for oncology and hematology therapeutics.
December 14th 2021
In metastatic breast cancer (mBC) resistant to multiple lines, Herzuma (a trastuzumab biosimilar) plus gedatolisib, an mTOR/PI3K signaling pathway inhibitor, demonstrated value.
December 13th 2021
After a switch to a biosimilar, patients and their oncologists may not always agree on how well the switch was described or whether the patient felt involved.
December 12th 2021
By Skylar Jeremias
Etanercept and adalimumab biosimilar competition is not only necessary to drive down prices, it’s long overdue, according to Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute.
December 11th 2021
Tot Biopharm receives China regulatory approval for a bevacizumab biosimilar and Fujifilm moves forward with plans for a Suzhou Innovation and Collaboration Center.
December 9th 2021
The trial included "drifted" (nonstandard) reference product, forcing a stratified analysis to yield relevant data.
